Skip to main content
. 2017 Jul;153(1):178–190.e10. doi: 10.1053/j.gastro.2017.03.053

Figure 6.

Figure 6

IL6 protects from DSS-induced colitis. (A–E) Administration of vehicle or recombinant IL6 to DSS-treated mice. (A) Body weight following IL6 or vehicle administration during DSS treatment (n ≥3). (B) FITC-dextran concentration in serum as readout for intestinal permeability (n ≥3). (C) Number of BrdU+ IECs per crypt (30–40 crypts per mouse were counted, n = 3 mice). (D) pSTAT3 IHC of DSS-treated colons. Scale bars 50 μm. (E) Quantification of pSTAT3+ IECs per crypt (30 crypts per mouse were counted, n ≥4). (F–I) Antibody-mediated IL6 depletion during DSS-induced colitis in wild-type mice. (F) Body weight of IL6-depleted mice and controls during DSS treatment (n ≥3). (G) FITC-dextran concentration in serum as readout for intestinal permeability (n ≥7). Quantification of (H) BrdU+ IECs per crypt (30–80 crypts per mouse were counted, n ≥4) and (I) pSTAT3+ IECs per crypt (30–80 crypts per mouse were counted, n ≥3). All data are mean ± SEM. *P < .05, **P < .01, ***P < .001, t test except (A and F), 2-way analysis of variance.